SYROS PHARMACEUTICALS INC's ticker is and the CUSIP is 87184Q206. A total of 55 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,361 | +64.2% | 263,691 | +70.1% | 0.01% | +50.0% |
| Q1 2024 | $829 | +2.9% | 154,989 | +49.7% | 0.01% | +20.0% |
| Q4 2023 | $806 | +88.8% | 103,522 | -4.3% | 0.01% | +25.0% |
| Q3 2023 | $427 | +14.5% | 108,137 | -8.7% | 0.00% | +33.3% |
| Q2 2023 | $373 | +14.8% | 118,398 | -2.6% | 0.00% | 0.0% |
| Q1 2023 | $325 | +164.2% | 121,555 | +255.8% | 0.00% | +50.0% |
| Q4 2022 | $123 | – | 34,165 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 1,786,427 | $9,217,963 | 1.93% |
| Bain Capital Life Sciences Investors, LLC | 2,749,808 | $14,189,009 | 1.56% |
| Opaleye Management Inc. | 865,443 | $4,465,686 | 1.02% |
| Omega Fund Management, LLC | 251,270 | $1,296,553 | 0.96% |
| Flagship Pioneering Inc. | 1,293,849 | $6,676,261 | 0.79% |
| Exome Asset Management LLC | 159,175 | $821,344 | 0.72% |
| Blue Owl Capital Holdings LP | 340,855 | $1,758,812 | 0.49% |
| Avidity Partners Management LP | 1,673,538 | $8,635,456 | 0.37% |
| Artal Group S.A. | 2,505,013 | $12,925,867 | 0.33% |
| SUPERSTRING CAPITAL MANAGEMENT LP | 37,789 | $194,991 | 0.25% |